Search | Clinical Trials Finder

Conditions: Advanced Non-small Cell Lung Cancer
Interventions: Atezolizumab; Drug
Lead sponsor: Liza Villaruz, MD; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 2
States / cities: Orlando, Florida • Pittsburgh, Pennsylvania

Conditions: Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
Interventions: Nivolumab; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 80 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Denver, Colorado

Conditions: Locally Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma
Interventions: Bintrafusp Alfa, Pemetrexed, Carboplatin, Cisplatin; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung, Lung Cancer, Nonsquamous Nonsmall Cell Neoplasm of Lung
Interventions: NEO-PV-01, Pembrolizumab, Adjuvant, Carboplatin, Pemetrexed; Biological · Other · Drug
Lead sponsor: BioNTech US Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Santa Monica, California • Boston, Massachusetts • St Louis, Missouri + 1 more

Conditions: Breast Cancer, Colorectal Cancer, Uveal Melanoma, Cutaneous Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Interventions: TBio-4101, Pembrolizumab; Biological · Drug
Lead sponsor: Turnstone Biologics, Corp.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 11
States / cities: Irvine, California • Hollywood, Florida • Miami, Florida + 8 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer
Interventions: Durvalumab, Cisplatin, Carboplatin, Etoposide; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 2
States / cities: Houston, Texas • Fairfax, Virginia

Conditions: Non Small Cell Lung Cancer
Interventions: Not listed
Lead sponsor: N-Power Medicine; Industry
Eligibility: 18 Years and older
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 8
States / cities: Monterey, California • Dover, Delaware • Milford, Delaware + 5 more

Conditions: Non-small Cell Lung Cancer, NSCLC
Interventions: PembroRT; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Non-small Cell Lung Cancer
Interventions: Calderasib, Pembrolizumab (+) Berahyaluronidase alfa, Pemetrexed, Cisplatin, Carboplatin; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 675 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 10
States / cities: Birmingham, Alabama • Farmington, Connecticut • Stamford, Connecticut + 7 more

Conditions: Advanced Non-Small Cell Lung Cancer
Interventions: BNT116, Cemiplimab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 9
States / cities: Los Angeles, California • Santa Monica, California • Louisville, Kentucky + 6 more

Conditions: Non Small Cell Lung Cancer
Interventions: [18F]F AraG; Drug
Lead sponsor: CellSight Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 3
States / cities: Palo Alto, California • Sacramento, California • Stony Brook, New York

Conditions: Stage III Cutaneous Melanoma, Stage IV Cutaneous Melanoma, Locally Advanced Melanoma, Locally Advanced Solid Neoplasm, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Urothelial Carcinoma, Non-Small Cell Lung Carcinoma, Stage IB Lung Cancer AJCC v7, Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Abexinostat, Pembrolizumab; Drug · Biological
Lead sponsor: Rahul Aggarwal; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small Cell Lung Cancer
Interventions: Nivolumab, Ipilimumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 10
States / cities: Springdale, Arkansas • New Haven, Connecticut • Jacksonville, Florida + 6 more

Conditions: Non-Small Cell Lung Cancer
Interventions: Atezolizumab, Tiragolumab, Matching Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 620 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 9
States / cities: Denver, Colorado • New Haven, Connecticut • St. Petersburg, Florida + 6 more

Conditions: Non-small Cell Lung Cancer
Interventions: Nivolumab, Relatlimab, Pembrolizumab, Carboplatin, Pemetrexed, Cisplatin; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 50
States / cities: Mobile, Alabama • Tucson, Arizona • Los Angeles, California + 47 more

Conditions: Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions: PF-07257876; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 39
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more

Conditions: Non Small Cell Lung Cancer NSCLC
Interventions: Durvalumab, Tremelimumab, Abraxane + carboplatin, Gemcitabine + cisplatin, Gemcitabine + carboplatin, Pemetrexed + carboplatin, Pemetrexed + cisplatin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 16
States / cities: Phoenix, Arizona • Bakersfield, California • Santa Monica, California + 13 more

Conditions: Non-small Cell Lung Cancer
Interventions: Pumitamig, Docetaxel; Drug
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 5
States / cities: Birmingham, Alabama • Tampa, Florida • Elizabethtown, Kentucky + 2 more

Conditions: Carcinoma, Non-Small-Cell Lung
Interventions: Carotuximab (TRC105), OPDIVO; Drug
Lead sponsor: Tracon Pharmaceuticals Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 2
States / cities: Birmingham, Alabama • Tampa, Florida

Conditions: Melanoma, Non-small Cell Lung Cancer, Brain Metastasis
Interventions: Pembrolizumab plus Bevacizumab; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2025
U.S. locations: 2
States / cities: New Haven, Connecticut • Tampa, Florida

Conditions: Metastatic NSCLC - Non-Small Cell Lung Cancer, Locally Advanced NSCLC - Non-Small Cell Lung Cancer
Interventions: inupadenant, Placebo, Carboplatin, Pemetrexed; Drug
Lead sponsor: iTeos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fayetteville, Arkansas • Tampa, Florida

Conditions: Metastatic Non-Small Cell Lung Cancer
Interventions: Pembrolizumab, Lenvatinib, Docetaxel; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 28
States / cities: Bakersfield, California • Fleming Island, Florida • Orange City, Florida + 24 more

Conditions: Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
Interventions: N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK, N-803 + Docetaxel + Pembrolizumab, N-803 + Docetaxel + Nivolumab; Drug
Lead sponsor: ImmunityBio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 35
States / cities: Anchorage, Alaska • Hot Springs, Arkansas • El Segundo, California + 31 more

Conditions: Advanced Squamous Non-Small Cell Lung Carcinoma
Interventions: RBN-2397; Drug
Lead sponsor: Ribon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Newark, Delaware • Newnan, Georgia • Baton Rouge, Louisiana + 1 more

Search by objective public record fields.

Evaluating the Efficacy of Atezolizumab in Advanced Non-small Cell Lung Cancer (NSCLC)

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer

A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer

A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer

An External Control Arm Study in Non-Small Cell Lung Cancer

The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)

Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer

Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)

A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC

Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)

Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer

Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008)

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

RBN-2397 in Combination With Pembrolizumab in Patients With SCCL